NEUROPROTECTIVE EVALUATION OF N-BENZYL-2-[4-(ARYL)-1H-1,2,3-TRIAZOL-1-YL]ETHAN-1-IMINEOXIDES

Despite the undeniable achievements of medicinal chemistry in the search for new compounds with neuroprotective activity, there is currently no approved effective drug with a promising profile to effectively treat neurodegenerative diseases, including Alzheimer’s and Parkinson’s, among others. Four...

Descripción completa

Detalles Bibliográficos
Autores: Arribas, Raquel L., Los Ríos, Cristóbal de, Głowacka, Iwona E., Marco-Contelles, José, Piotrowska, Dorota G.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2026
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:dnet:digitalcsic_::5a41cd060043970ba81611e4019b02c8
Acceso en línea:http://hdl.handle.net/10261/427746
https://api.elsevier.com/content/abstract/scopus_id/105033099558
Access Level:acceso abierto
Palabra clave:1,2,3-triazole-derived nitrones
neuroprotective activity
per se toxicity
id ES_cece2933a80fc8cb603dc66bafa2f2d5
oai_identifier_str oai:dnet:digitalcsic_::5a41cd060043970ba81611e4019b02c8
network_acronym_str ES
network_name_str España
repository_id_str
spelling NEUROPROTECTIVE EVALUATION OF N-BENZYL-2-[4-(ARYL)-1H-1,2,3-TRIAZOL-1-YL]ETHAN-1-IMINEOXIDESArribas, Raquel L.Los Ríos, Cristóbal deGłowacka, Iwona E.Marco-Contelles, JoséPiotrowska, Dorota G.1,2,3-triazole-derived nitronesneuroprotective activityper se toxicityDespite the undeniable achievements of medicinal chemistry in the search for new compounds with neuroprotective activity, there is currently no approved effective drug with a promising profile to effectively treat neurodegenerative diseases, including Alzheimer’s and Parkinson’s, among others. Four representative N-benzyl-2-[4-(aryl)-1H-1,2,3-triazol-1-yl]ethan-1-imine oxides, which have been shown to be good antioxidants, were selected to evaluate their neuroprotective potency. N-Benzyl-2-[4-(4-fluorophenyl)-1H-1,2,3-triazol-1-yl]ethan-1-imine oxide (2) exhibited strong antioxidant effects comparable to melatonin; however, the lack of efficacy in reversing okadaic acid-induced toxicity highlights the need for further structural optimization to broaden its neuroprotective spectrum.RLA thanks the Spanish Ministry of Economy and Competitiveness (CNS2022-135290, Consolidación Investigadora Program).Peer reviewedPolish Pharmaceutical SocietyMinisterio de Economía y Competitividad (España)Arribas, Raquel L. [0000-0002-2507-1521]Los Ríos, Cristóbal de [0000-0002-6456-7589]Głowacka, Iwona E. [0000-0001-7567-5860]Marco-Contelles, José [0000-0003-0690-0328]Piotrowska, Dorota G. [0000-0003-3792-8796]Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202620262026info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionhttp://hdl.handle.net/10261/427746https://api.elsevier.com/content/abstract/scopus_id/105033099558reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)InglésActa Poloniae Pharmaceutica Drug Researchhttps://doi.org/10.32383/appdr/216268Síinfo:eu-repo/semantics/openAccessoai:dnet:digitalcsic_::5a41cd060043970ba81611e4019b02c82026-05-22T06:33:51Z
dc.title.none.fl_str_mv NEUROPROTECTIVE EVALUATION OF N-BENZYL-2-[4-(ARYL)-1H-1,2,3-TRIAZOL-1-YL]ETHAN-1-IMINEOXIDES
title NEUROPROTECTIVE EVALUATION OF N-BENZYL-2-[4-(ARYL)-1H-1,2,3-TRIAZOL-1-YL]ETHAN-1-IMINEOXIDES
spellingShingle NEUROPROTECTIVE EVALUATION OF N-BENZYL-2-[4-(ARYL)-1H-1,2,3-TRIAZOL-1-YL]ETHAN-1-IMINEOXIDES
Arribas, Raquel L.
1,2,3-triazole-derived nitrones
neuroprotective activity
per se toxicity
title_short NEUROPROTECTIVE EVALUATION OF N-BENZYL-2-[4-(ARYL)-1H-1,2,3-TRIAZOL-1-YL]ETHAN-1-IMINEOXIDES
title_full NEUROPROTECTIVE EVALUATION OF N-BENZYL-2-[4-(ARYL)-1H-1,2,3-TRIAZOL-1-YL]ETHAN-1-IMINEOXIDES
title_fullStr NEUROPROTECTIVE EVALUATION OF N-BENZYL-2-[4-(ARYL)-1H-1,2,3-TRIAZOL-1-YL]ETHAN-1-IMINEOXIDES
title_full_unstemmed NEUROPROTECTIVE EVALUATION OF N-BENZYL-2-[4-(ARYL)-1H-1,2,3-TRIAZOL-1-YL]ETHAN-1-IMINEOXIDES
title_sort NEUROPROTECTIVE EVALUATION OF N-BENZYL-2-[4-(ARYL)-1H-1,2,3-TRIAZOL-1-YL]ETHAN-1-IMINEOXIDES
dc.creator.none.fl_str_mv Arribas, Raquel L.
Los Ríos, Cristóbal de
Głowacka, Iwona E.
Marco-Contelles, José
Piotrowska, Dorota G.
author Arribas, Raquel L.
author_facet Arribas, Raquel L.
Los Ríos, Cristóbal de
Głowacka, Iwona E.
Marco-Contelles, José
Piotrowska, Dorota G.
author_role author
author2 Los Ríos, Cristóbal de
Głowacka, Iwona E.
Marco-Contelles, José
Piotrowska, Dorota G.
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Ministerio de Economía y Competitividad (España)
Arribas, Raquel L. [0000-0002-2507-1521]
Los Ríos, Cristóbal de [0000-0002-6456-7589]
Głowacka, Iwona E. [0000-0001-7567-5860]
Marco-Contelles, José [0000-0003-0690-0328]
Piotrowska, Dorota G. [0000-0003-3792-8796]
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv 1,2,3-triazole-derived nitrones
neuroprotective activity
per se toxicity
topic 1,2,3-triazole-derived nitrones
neuroprotective activity
per se toxicity
description Despite the undeniable achievements of medicinal chemistry in the search for new compounds with neuroprotective activity, there is currently no approved effective drug with a promising profile to effectively treat neurodegenerative diseases, including Alzheimer’s and Parkinson’s, among others. Four representative N-benzyl-2-[4-(aryl)-1H-1,2,3-triazol-1-yl]ethan-1-imine oxides, which have been shown to be good antioxidants, were selected to evaluate their neuroprotective potency. N-Benzyl-2-[4-(4-fluorophenyl)-1H-1,2,3-triazol-1-yl]ethan-1-imine oxide (2) exhibited strong antioxidant effects comparable to melatonin; however, the lack of efficacy in reversing okadaic acid-induced toxicity highlights the need for further structural optimization to broaden its neuroprotective spectrum.
publishDate 2026
dc.date.none.fl_str_mv 2026
2026
2026
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/427746
https://api.elsevier.com/content/abstract/scopus_id/105033099558
url http://hdl.handle.net/10261/427746
https://api.elsevier.com/content/abstract/scopus_id/105033099558
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Acta Poloniae Pharmaceutica Drug Research
https://doi.org/10.32383/appdr/216268
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Polish Pharmaceutical Society
publisher.none.fl_str_mv Polish Pharmaceutical Society
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869420024310005760
score 15,811543

Similares en LA Referencia